Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) EBIT: د.إ81 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ADX:JULPHAR Gulf Pharmaceutical Industries PSC ADX:JULPHAR
54 GF Score
Price د.إ1.04
GF Value د.إ1.09
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Gulf Pharmaceutical Industries PSC EBIT?

Gulf Pharmaceutical Industries PSC ADX:JULPHAR +0.97% 54 EBIT is د.إ81 Mil as of Mar. 2026. GuruFocus rates ADX:JULPHAR with a GF Score™ of 54/100 and a GF Value™ of د.إ1.09 (Fairly Valued). The stock has 5 warning signs investors should review.

Gulf Pharmaceutical Industries PSC's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was د.إ35 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was د.إ81 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Gulf Pharmaceutical Industries PSC's annualized ROC % for the quarter that ended in Mar. 2026 was 8.89%. Gulf Pharmaceutical Industries PSC's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 13.56%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Gulf Pharmaceutical Industries PSC's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 6.60%.

Gulf Pharmaceutical Industries PSC  (ADX:JULPHAR) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Gulf Pharmaceutical Industries PSC's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=119.2 * ( 1 - 10.97% )/( (1207.9 + 1179.8)/ 2 )
=106.12376/1193.85
=8.89 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1779.8 - 303.3 - ( 268.6 - max(0, 476.6 - 1485.3+268.6))
=1207.9

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1862.1 - 420.6 - ( 261.7 - max(0, 549.2 - 1569.8+261.7))
=1179.8

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Gulf Pharmaceutical Industries PSC's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=140.4/( ( (254.5 + max(768.8, 0)) + (252.2 + max(795.8, 0)) )/ 2 )
=140.4/( ( 1023.3 + 1048 )/ 2 )
=140.4/1035.65
=13.56 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(516.1 + 400.9 + 325.3) - (303.3 + 0 + 170.2)
=768.8

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(598 + 398.3 + 330) - (420.6 + 0 + 109.9)
=795.8

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Gulf Pharmaceutical Industries PSC's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=80.9/1224.837
=6.60 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gulf Pharmaceutical Industries PSC EBIT Related Terms

Gulf Pharmaceutical Industries PSC EBIT Historical Data

* Premium members only.

The historical data trend for Gulf Pharmaceutical Industries PSC's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gulf Pharmaceutical Industries PSC EBIT Chart

Gulf Pharmaceutical Industries PSC Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 66.70 16.20 -5.80 53.20 75.70

Gulf Pharmaceutical Industries PSC Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.90 27.00 10.30 8.50 35.10

ADX:JULPHAR vs MCK, CAH, COR: EBIT Comparison

For the Medical Distribution subindustry, Gulf Pharmaceutical Industries PSC's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gulf Pharmaceutical Industries PSC EV-to-EBIT vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Gulf Pharmaceutical Industries PSC's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Gulf Pharmaceutical Industries PSC's EV-to-EBIT falls into.


ADX:JULPHAR
54GF Score
Gulf Pharmaceutical Industries PSC ADX:JULPHAR
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gulf Pharmaceutical Industries PSC EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was د.إ81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of د.إ81 Mil mean?
Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) has a EBIT of د.إ81 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Gulf Pharmaceutical Industries PSC.
Is Gulf Pharmaceutical Industries PSC's EBIT too high?
Gulf Pharmaceutical Industries PSC's current EBIT is د.إ81 Mil. Overall, Gulf Pharmaceutical Industries PSC has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gulf Pharmaceutical Industries PSC's EBIT compare to MCK and CAH?
Gulf Pharmaceutical Industries PSC's EBIT of د.إ81 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Distribution company?
A good EBIT depends on the Medical Distribution industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Gulf Pharmaceutical Industries PSC. Gulf Pharmaceutical Industries PSC's current EBIT is د.إ81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gulf Pharmaceutical Industries PSC stock overvalued right now?
Based on GuruFocus' analysis, Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) is currently considered Fairly Valued. The stock's GF Value™ is د.إ1.09, compared to a current price of د.إ1.04 — trading 4.6% below its estimated fair value. The current EBIT is د.إ81 Mil. Gulf Pharmaceutical Industries PSC's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Gulf Pharmaceutical Industries PSC (ADX:JULPHAR), the current EBIT is د.إ81 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Gulf Pharmaceutical Industries PSC stock appears to be undervalued. The current stock price of د.إ1.04 is trading 4.6% below its estimated GF Value™ of د.إ1.09. GuruFocus considers Gulf Pharmaceutical Industries PSC to be Fairly Valued.

Key valuation signals for ADX:JULPHAR:

  • EBIT: د.إ81 Mil
  • GF Value™: د.إ1.09 vs. price of د.إ1.04 (4.6% below fair value)
  • GF Score™: 54/100 with 5 warning signs

No single metric tells the full story. See the ADX:JULPHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gulf Pharmaceutical Industries PSC Business Description

Address Airport Road, P.O. Box 997, Digdaga, Ras Al Khaimah, ARE
Gulf Pharmaceutical Industries PSC is in the business of manufacturing and selling medicines, drugs, and various other types of pharmaceutical and medical compounds in addition to cosmetic compounds. The company operates in four segments: Manufacturing, Trading, Investments, and others. The majority of its revenue is generated from the Manufacturing segment. The geographical segments are UAE, Other GCC countries, and Other countries. It derives maximum revenue from UAE. Its business is centered around General Medicines in the retail pharmacy channel and hospitals as well as speciality Products. Its medicines also targets therapeutic segments such as Diabetes, Gastrointestinal Tract (GIT), Respiratory, Wounds and Scars, Anti-infectives, Anemia, Gynecology, Erectile Dysfunction and Others.
54GF Score

Get the complete analysis for ADX:JULPHAR

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

د.إ1.04
Price
د.إ1.09
GF Value